Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Verona Pharma participates in a conference call with SunTrust » 13:15
03/31/20
03/31
13:15
03/31/20
13:15
VRNA

Verona Pharma

$4.03 /

+0.53 (+15.14%)

Analyst Lee holds a…

Analyst Lee holds a conference call with management on March 31 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Verona Pharma participates in a conference call with SunTrust » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
VRNA

Verona Pharma

$3.50 /

-0.16 (-4.37%)

Analyst Lee holds a…

Analyst Lee holds a conference call with management on March 31 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
Verona Pharma participates in a conference call with SunTrust » 11:53
03/27/20
03/27
11:53
03/27/20
11:53
VRNA

Verona Pharma

$3.59 /

-0.48 (-11.79%)

Analyst Lee holds a…

Analyst Lee holds a conference call with management on March 31 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Verona Pharma trading resumes  14:26
02/26/20
02/26
14:26
02/26/20
14:26
VRNA

Verona Pharma

$6.09 /

-0.21 (-3.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Verona Pharma trading halted, volatility trading pause  14:16
02/26/20
02/26
14:16
02/26/20
14:16
VRNA

Verona Pharma

$5.95 /

-0.35 (-5.56%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Verona Pharma appoints Dr. David Zaccardelli as CEO, Mark Hahn as CFO » 05:19
02/03/20
02/03
05:19
02/03/20
05:19
VRNA

Verona Pharma

$5.48 /

-0.07 (-1.26%)

Verona Pharma announces…

Verona Pharma announces that David Zaccardelli, Pharm. D., has been appointed President and CEO with effect from February 1. Dr. Zaccardelli has also joined the board of Verona Pharma. Dr. Zaccardelli brings substantial specialty pharmaceutical leadership and operational expertise, including most notably, serving as President and CEO of Dova Pharmaceuticals, until its acquisition by Swedish Orphan Biovitrum AB in November 2019. Jan-Anders Karlsson, Ph.D., Verona Pharma's previous CEO, is retiring following 8 years of dedicated service to the company to pursue non-executive roles and he has agreed to provide support to ensure an effective transition. In addition, Mark Hahn will join Verona Pharma as CFO, a non-board position, with effect from March 1. Hahn previously served as the CFO of Dova Pharmaceuticals. Piers Morgan will continue to serve as CFO of Verona Pharma through February 28 to provide an efficient transition and complete required financial reporting. Both Dr. Zaccardelli and Mr. Hahn will be based in North Carolina, where the majority of the company's clinical team are located, to lead the development and commercialization of ensifentrine for respiratory diseases including chronic obstructive pulmonary disease, or COPD, asthma and cystic fibrosis, or CF.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Verona Pharma price target raised to $34 from $29 at SunTrust » 09:05
01/14/20
01/14
09:05
01/14/20
09:05
VRNA

Verona Pharma

$7.22 /

+1.24 (+20.74%)

SunTrust analyst Joon Lee…

SunTrust analyst Joon Lee raised his price target on Verona Pharma to $34 and kept his Buy rating after the release of a "positive" Phase 2b data on nebulized ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease. The analyst sees the FEV1 dose-response as highly promising ahead of its Phase 3 study and believes that Ensifentrine is undervalued in what could be a $1B global sales opportunity in COPD alone.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Verona Pharma price target raised to $60 after Phase 2b COPD study hits » 12:43
01/13/20
01/13
12:43
01/13/20
12:43
VRNA

Verona Pharma

$7.02 /

+1.04 (+17.39%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos raised her price target on Verona Pharma shares to $60 from $58 after the company's Phase 2b dose-ranging study evaluating nebulized ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease met its primary endpoint of improved lung function. Moussatos keeps an Outperform rating on Verona shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Verona Pharma jumps 45% after study meets primary endpoint at all doses  09:11
01/13/20
01/13
09:11
01/13/20
09:11
VRNA

Verona Pharma

$5.98 /

+0.38 (+6.79%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Verona Pharma says Phase 2b COPD study met primary endpoint at all doses » 09:11
01/13/20
01/13
09:11
01/13/20
09:11
VRNA

Verona Pharma

$5.98 /

+0.38 (+6.79%)

Verona Pharma announced…

Verona Pharma announced top-line data from a 4 week, 416 patient, Phase 2b dose-ranging study evaluating nebulized ensifentrine or placebo as an add-on treatment to tiotropium, a long acting anti-muscarinic bronchodilator, in patients with moderate to severe chronic obstructive pulmonary disease. The study met its primary endpoint of improved lung function, with ensifentrine added on to inhaled tiotropium, a LAMA commonly used to treat COPD. Ensifentrine produced a clinically and statistically significant, and dose-dependent improvement in peak forced expiratory volume in one second at week 4 compared to placebo added on to tiotropium. Highlights for ensifentrine as an add-on to tiotropium: Primary endpoint met at all doses: statistically significant and clinically meaningful improvement in lung function at week 4. Improvements ranged from 78 mL for the 0.375 mg dose to 124 mL for the 3.0 mg dose. Effects were maintained over 4 weeks. Dose-dependent improvements in lung function were observed on both peak FEV1 and FEV1 AUC 0-12 hours2. Statistically significant improvement in average FEV1 AUC 0-12 hours of 87 mL for the 3.0 mg dose is supportive of twice daily dosing.Clinically meaningful improvements in health-related quality of life were observed on top of tiotropium, exceeding the minimal clinically important difference of 4 units compared to placebo at week 4, with the two highest doses also achieving statistical significance. Ensifentrine was well tolerated at all doses with an adverse event profile similar to placebo. These data support dose selection for Phase 3.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.